Citius Oncology, Inc. (CTOR)

Citius Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022
Net Income	-24.76	-21.15	-12.7	-10.87
Stock-Based Compensation	8.32	7.5	1.97	-
Other Operating Activities	1.06	0.58	0.58	1.15
Change in Inventory	-12.65	-2.13	-	-
Change in Accounts Payable	9.52	2.42	1.2	0.18
Change in Other Net Operating Assets	13.02	12.91	8.96	9.53
Operating Cash Flow	-5.49	0.13	-	-
Sale (Purchase) of Intangibles	-5.75	-5	-	-
Investing Cash Flow	-5.75	-5	-	-
Long-Term Debt Issued	-	3.8	-	-
Net Debt Issued (Repaid)	-	3.8	-	-
Issuance of Common Stock	15.17	-	-	-
Other Financing Activities	-	1.07	-	-
Financing Cash Flow	15.17	4.87	-	-
Net Cash Flow	3.92	0	-	-
Cash Interest Paid	0.19	-	-	-
Levered Free Cash Flow	-8.13	-1.94	4.55	-
Unlevered Free Cash Flow	-7.99	-1.94	4.55	-
Change in Working Capital	9.89	13.2	10.16	9.71

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q